Head-to-head evidence
Mezagitamab vs TJ202
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Multiple Myeloma
Shared mechanism: CD38 · full Multiple Myeloma pipeline
Mezagitamab
Developed by Takeda Pharmaceutical Company
NCT03439280 · Phase 1/2 · completed
This was a nonrandomized, open-label, single-arm dose-escalation study of 50 participants, with no placebo or active comparator. Its primary outcomes focused on safety, including treatment-emergent adverse events and dose-limiting toxicities, rather than a controlled efficacy comparison; 50 of 50 participants reported at least one treatment-emergent adverse event, and 1 of 41 dose-limiting-toxicity-evaluable participants had a dose-limiting toxicity.
TJ202
Developed by TJ Biopharma Co., Ltd.
NCT03952091 · Phase 3 · completed
The study randomly assigned 289 participants to TJ202 plus lenalidomide and dexamethasone or to the active comparator regimen, but it was open-label rather than blinded. Its primary endpoint was the clinical measure of progression-free survival; because no results are posted, it is not possible to determine whether this endpoint was met.
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Mezagitamab's landscape · TJ202's landscape